
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
An oral bisphosphonate may slow the development of symptomatic bone metastases and reduce the risk of death from this disease, new data show.





